Anand Dalal
Overview
Explore the profile of Anand Dalal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akinola I, Cusatis R, Pasquini M, Shaw B, Bollu V, Dalal A, et al.
Transplant Cell Ther
. 2023 Jan;
29(4):254.e1-254.e9.
PMID: 36634738
Toxicities after chimeric antigen receptor T cell (CAR-T) therapy are well known, yet the patient experience during and after CAR-T therapy has not been well described outside of the trial...
2.
Maziarz R, Yang H, Liu Q, Wang T, Zhao J, Lim S, et al.
Leuk Lymphoma
. 2022 Apr;
63(9):2052-2062.
PMID: 35422192
This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel...
3.
Pennell N, Mutebi A, Zhou Z, Ricculli M, Tang W, Wang H, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-9.
PMID: 35100695
Purpose: The aim of the current study was to assess the economic impact of using next-generation sequencing (NGS) versus single-gene testing strategies among patients with metastatic non-small-cell lung cancer (mNSCLC)...
4.
Qi C, Bollu V, Yang H, Dalal A, Zhang S, Zhang J
Clin Ther
. 2021 Aug;
43(8):1300-1319.e8.
PMID: 34380609
Purpose: To assess the cost-effectiveness and cost-effective price of tisagenlecleucel, a novel, effective chimeric antigen receptor T-cell therapy, versus salvage chemotherapy (SC) for the treatment of relapsed or refractory diffuse...
5.
Horn L, Bauml J, Forde P, Davis K, Myall N, Sasane M, et al.
Lung Cancer
. 2019 Jan;
128:74-90.
PMID: 30642457
Introduction: Clinical outcomes data on BRAF-mutated non-small cell lung cancer (NSCLC) patients treated in routine practice is limited. To address this gap, we described treatment patterns and survival in a...
6.
Nellesen D, Dea K, Guerin A, Culver K, Mutebi A, Dalal A
Am J Manag Care
. 2018 Apr;
24(2 Spec No.):SP37-SP42.
PMID: 29689141
No abstract available.
7.
Zhou Z, Mutebi A, Han S, Bensimon A, Ricculli M, Xie J, et al.
J Med Econ
. 2018 Feb;
21(6):577-586.
PMID: 29458286
Aims: To assess the cost-effectiveness of first-line ceritinib vs crizotinib and platinum doublet chemotherapy for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) from a US third-party payer's...
8.
Basu A, Dalal A, Canonica G, Forshag M, Yancey S, Nagar S, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2017 Mar;
17(2):121-131.
PMID: 28277854
Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated...
9.
Blanchette C, Akazawa M, Dalal A, Simoni-Wastila L
Am J Geriatr Pharmacother
. 2008 Sep;
6(3):138-46.
PMID: 18775388
Background: Cost-effective treatments for chronic obstructive pulmonary disease (COPD) are needed to reduce the burden on the Medicare system. Objectives: The objectives of this retrospective study were to compare the...
10.
Akazawa M, Halpern R, Riedel A, Stanford R, Dalal A, Blanchette C
Respir Med
. 2008 Sep;
102(12):1744-52.
PMID: 18760581
Background: In the United States, chronic obstructive pulmonary disease (COPD) diagnosis is often a lengthy process, and consequently results in delays in treatment in early stages. Disease progression and complication...